SG11201408318RA - Compositions and methods for transmucosal absorption - Google Patents
Compositions and methods for transmucosal absorptionInfo
- Publication number
- SG11201408318RA SG11201408318RA SG11201408318RA SG11201408318RA SG11201408318RA SG 11201408318R A SG11201408318R A SG 11201408318RA SG 11201408318R A SG11201408318R A SG 11201408318RA SG 11201408318R A SG11201408318R A SG 11201408318RA SG 11201408318R A SG11201408318R A SG 11201408318RA
- Authority
- SG
- Singapore
- Prior art keywords
- lllll
- new york
- international
- methods
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Inorganic Chemistry (AREA)
- Anesthesiology (AREA)
- Psychiatry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Steroid Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261660593P | 2012-06-15 | 2012-06-15 | |
| US201261667774P | 2012-07-03 | 2012-07-03 | |
| US201261725402P | 2012-11-12 | 2012-11-12 | |
| US201361792900P | 2013-03-15 | 2013-03-15 | |
| PCT/US2013/046023 WO2013188847A1 (en) | 2012-06-15 | 2013-06-14 | Compositions and methods for transmucosal absorption |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201408318RA true SG11201408318RA (en) | 2015-01-29 |
Family
ID=49758769
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201408318RA SG11201408318RA (en) | 2012-06-15 | 2013-06-14 | Compositions and methods for transmucosal absorption |
| SG10201605407TA SG10201605407TA (en) | 2012-06-15 | 2013-06-14 | Compositions and methods for transmucosal absorption |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201605407TA SG10201605407TA (en) | 2012-06-15 | 2013-06-14 | Compositions and methods for transmucosal absorption |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20140171515A1 (zh) |
| EP (1) | EP2861223B1 (zh) |
| JP (5) | JP6259452B2 (zh) |
| CN (2) | CN104684550A (zh) |
| AR (1) | AR092330A1 (zh) |
| AU (2) | AU2013274003B2 (zh) |
| BR (1) | BR112014031394B1 (zh) |
| CA (2) | CA3118913C (zh) |
| DK (1) | DK2861223T3 (zh) |
| ES (1) | ES2929133T3 (zh) |
| HK (1) | HK1209361A1 (zh) |
| HR (1) | HRP20221325T1 (zh) |
| HU (1) | HUE060175T2 (zh) |
| IL (1) | IL236268B (zh) |
| LT (1) | LT2861223T (zh) |
| MX (2) | MX2021005317A (zh) |
| MY (1) | MY194495A (zh) |
| NZ (2) | NZ631144A (zh) |
| PL (1) | PL2861223T3 (zh) |
| PT (1) | PT2861223T (zh) |
| RS (1) | RS63822B1 (zh) |
| SG (2) | SG11201408318RA (zh) |
| SI (1) | SI2861223T1 (zh) |
| TW (3) | TWI590820B (zh) |
| WO (1) | WO2013188847A1 (zh) |
| ZA (1) | ZA201500288B (zh) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011062614A1 (en) | 2009-11-20 | 2011-05-26 | Tonix Pharmaceuticals, Inc. | Methods and compositions for treating symptoms associated with post-traumatic stress disorder using cyclobenzaprine |
| US20110319389A1 (en) | 2010-06-24 | 2011-12-29 | Tonix Pharmaceuticals, Inc. | Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine |
| CA2904812C (en) | 2013-03-15 | 2021-07-20 | Tonix Pharmaceuticals, Inc. | Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride |
| WO2016044796A1 (en) | 2014-09-18 | 2016-03-24 | Seth Lederman | Eutectic formulations of cyclobenzaprine hydrochloride |
| RU2018102640A (ru) * | 2015-07-15 | 2019-08-15 | Теранексю | Применение амитриптилина для блокирования мозговых гемиканалов и способ потенцирования его влияния in vivo |
| WO2018045367A1 (en) * | 2016-09-02 | 2018-03-08 | Nova Southeastern University | Atropine sulfate rapidly-disintegrating sublingual tablets for treatment of acute organophosphate toxicity |
| US11517557B2 (en) * | 2017-07-13 | 2022-12-06 | Tonix Pharmaceuticals Holding Corp. | Analogs of cyclobenzaprine and amitriptyline |
| CN107519142B (zh) * | 2017-08-24 | 2021-02-26 | 正大制药（青岛）有限公司 | 一种盐酸环苯扎林舌下片及其制备方法 |
| CN107496355B (zh) * | 2017-08-24 | 2021-04-30 | 正大制药（青岛）有限公司 | 一种盐酸环苯扎林舌下喷雾剂及其制备方法 |
| MX2020004105A (es) * | 2017-12-08 | 2020-09-22 | Hoffmann La Roche | Formulacion farmaceutica. |
| CA3083341A1 (en) | 2017-12-11 | 2019-06-20 | Tonix Pharma Holdings Limited | Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions |
| CN108721240A (zh) * | 2018-06-08 | 2018-11-02 | 华益药业科技(安徽)有限公司 | 一种25mg阿米替林薄膜包衣片处方和工艺规程 |
| JP2021534192A (ja) * | 2018-08-20 | 2021-12-09 | トニックス ファーマ ホールディングス リミテッド | 急性ストレス障害および外傷後ストレス障害を処置する方法 |
| US20220339124A1 (en) * | 2019-09-30 | 2022-10-27 | Cadila Healthcare Limited | Intranasal pharmaceutical compositions of cyclobenzaprine |
| US20210315841A1 (en) * | 2020-04-08 | 2021-10-14 | Tonix Pharmaceuticals Holding Corp. | Cyclobenzaprine treatment for sexual dysfunction |
| JP2023554597A (ja) * | 2020-11-20 | 2023-12-28 | トニックス ファーマシューティカルズ ホールディング コーポレイション | アルコール使用障害のためのシクロベンザプリン処置 |
| EP4255407A1 (en) | 2020-12-07 | 2023-10-11 | Tonix Pharmaceuticals Holding Corp. | Cyclobenzaprine treatment for fibromyalgia |
| WO2022170107A2 (en) | 2021-02-04 | 2022-08-11 | Tonix Pharmaceuticals Holding Corp. | An improved method of assessing clinical response in the treatment of ptsd symptoms |
| WO2023059728A1 (en) | 2021-10-06 | 2023-04-13 | Tonix Pharmaceuticals Holding Corp. | Cyclobenzaprine for treatment or prevention of sexual dysfunction associated with mental health conditions in female patients |
| US20230414536A1 (en) | 2022-06-21 | 2023-12-28 | Tonix Pharmaceuticals Holding Corp. | CYCLOBENZAPRINE TREATMENT FOR POST-ACUTE SEQUELAE OF (SARS)-CoV-2 INFECTION (PASC) |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4968507A (en) * | 1984-06-20 | 1990-11-06 | Merck & Co., Inc. | Controlled porosity osmotic pump |
| US20030077227A1 (en) * | 1997-10-01 | 2003-04-24 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system |
| WO1999018937A1 (en) * | 1997-10-16 | 1999-04-22 | Merck & Co., Inc. | New cyclobenzaprine composition |
| PT1077683E (pt) * | 1998-05-14 | 2003-04-30 | Alza Corp | Terapia anti-depressiva |
| WO2001012174A1 (en) | 1999-08-13 | 2001-02-22 | Vela Pharmaceuticals Inc. | Cyclobenzaprine for treating generalized anxiety disorder and compositions thereof |
| JP2003506484A (ja) | 1999-08-13 | 2003-02-18 | ベラ・ファーマシューティカルズ・インコーポレイテッド | 非常に低用量のシクロベンザプリンを使用する睡眠障害の処置または予防するための組成物使用 |
| WO2001089476A1 (en) * | 2000-05-19 | 2001-11-29 | Npd Llc | Chewing gums, lozenges, candies, tablets, liquids, and sprays for efficient delivery of medications and dietary supplements |
| WO2002094229A1 (en) * | 2001-05-24 | 2002-11-28 | Alexza Molecular Delivery Corporation | Delivery of muscle relaxants through an inhalation route |
| JP2006516963A (ja) * | 2003-02-04 | 2006-07-13 | クリサリス テクノロジーズ インコーポレイテッド | エアロゾル製剤及びブスピロン、ブプレノルフィン、トリアゾラム、シクロベンザプリン及びゾルピデムのエアロゾル送出 |
| US20090117054A1 (en) * | 2005-03-29 | 2009-05-07 | University Of Kentucky Research Foundation | Sublingual spray for the treatment of pain |
| US20090148532A1 (en) * | 2007-12-06 | 2009-06-11 | Venkatesh Gopi M | Preparation of controlled release skeletal muscle relaxant dosage forms |
| JP2009079060A (ja) * | 2008-10-15 | 2009-04-16 | Novadel Pharma Inc | 極性または非極性の、バッカルスプレーまたはカプセル |
| US20100266682A1 (en) * | 2008-12-10 | 2010-10-21 | Nipun Davar | Polyethylene glycol-coated sodium carbonate as a pharmaceutical excipient and compositions produced from the same |
| US20100247586A1 (en) * | 2009-03-27 | 2010-09-30 | Andreas Hugerth | Multi-Portion Intra-Oral Dosage Form With Organoleptic Properties |
| WO2011062614A1 (en) * | 2009-11-20 | 2011-05-26 | Tonix Pharmaceuticals, Inc. | Methods and compositions for treating symptoms associated with post-traumatic stress disorder using cyclobenzaprine |
| US20110319389A1 (en) * | 2010-06-24 | 2011-12-29 | Tonix Pharmaceuticals, Inc. | Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine |
| ITMI20110558A1 (it) * | 2011-04-06 | 2012-10-07 | Campiglio Consulting Srl | Composizione farmaceutica contenente ciclobenzaprina adatta alla somministrazione endonasale |
| CA2904812C (en) * | 2013-03-15 | 2021-07-20 | Tonix Pharmaceuticals, Inc. | Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride |
-
2013
- 2013-06-14 RS RS20221005A patent/RS63822B1/sr unknown
- 2013-06-14 SG SG11201408318RA patent/SG11201408318RA/en unknown
- 2013-06-14 AU AU2013274003A patent/AU2013274003B2/en active Active
- 2013-06-14 NZ NZ631144A patent/NZ631144A/en unknown
- 2013-06-14 US US13/918,692 patent/US20140171515A1/en active Pending
- 2013-06-14 TW TW102121267A patent/TWI590820B/zh active
- 2013-06-14 CN CN201380039522.6A patent/CN104684550A/zh active Pending
- 2013-06-14 JP JP2015517469A patent/JP6259452B2/ja active Active
- 2013-06-14 SI SI201332010T patent/SI2861223T1/sl unknown
- 2013-06-14 CN CN202010024102.2A patent/CN111388430A/zh active Pending
- 2013-06-14 MY MYPI2014703784A patent/MY194495A/en unknown
- 2013-06-14 DK DK13804115.7T patent/DK2861223T3/da active
- 2013-06-14 WO PCT/US2013/046023 patent/WO2013188847A1/en active Application Filing
- 2013-06-14 LT LTEPPCT/US2013/046023T patent/LT2861223T/lt unknown
- 2013-06-14 ES ES13804115T patent/ES2929133T3/es active Active
- 2013-06-14 AR ARP130102101A patent/AR092330A1/es not_active Application Discontinuation
- 2013-06-14 PL PL13804115.7T patent/PL2861223T3/pl unknown
- 2013-06-14 HU HUE13804115A patent/HUE060175T2/hu unknown
- 2013-06-14 TW TW107117266A patent/TWI683660B/zh active
- 2013-06-14 PT PT138041157T patent/PT2861223T/pt unknown
- 2013-06-14 SG SG10201605407TA patent/SG10201605407TA/en unknown
- 2013-06-14 EP EP13804115.7A patent/EP2861223B1/en active Active
- 2013-06-14 TW TW106117185A patent/TWI642429B/zh active
- 2013-06-14 CA CA3118913A patent/CA3118913C/en active Active
- 2013-06-14 MX MX2021005317A patent/MX2021005317A/es unknown
- 2013-06-14 CA CA2876902A patent/CA2876902C/en active Active
- 2013-06-14 HR HRP20221325TT patent/HRP20221325T1/hr unknown
- 2013-06-14 BR BR112014031394-6A patent/BR112014031394B1/pt active IP Right Grant
- 2013-06-14 NZ NZ726488A patent/NZ726488A/en unknown
- 2013-06-14 MX MX2014015436A patent/MX2014015436A/es unknown
-
2014
- 2014-12-15 IL IL236268A patent/IL236268B/en unknown
-
2015
- 2015-01-15 ZA ZA2015/00288A patent/ZA201500288B/en unknown
- 2015-10-16 HK HK15110186.6A patent/HK1209361A1/zh unknown
-
2017
- 2017-10-02 JP JP2017192713A patent/JP2017222726A/ja not_active Withdrawn
-
2018
- 2018-10-04 AU AU2018241128A patent/AU2018241128B2/en active Active
-
2019
- 2019-05-14 JP JP2019091262A patent/JP2019123757A/ja not_active Withdrawn
-
2021
- 2021-06-16 JP JP2021100154A patent/JP2021138765A/ja not_active Withdrawn
-
2024
- 2024-02-02 JP JP2024014696A patent/JP2024032964A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201408318RA (en) | Compositions and methods for transmucosal absorption | |
| SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201811491YA (en) | Quinazoline and indole compounds to treat medical disorders | |
| SG11201408261UA (en) | Syringe | |
| SG11201407851RA (en) | Synthesis of pyrrolo [2, 3 - b] pyridines | |
| SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201807778YA (en) | Bicyclic compounds for diagnosis and therapy | |
| SG11201808237UA (en) | Substituted indole compound derivatives as dengue viral replication inhibitors | |
| SG11201908786VA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201407655TA (en) | Therapeutic uses of fibroblast growth factor 21 proteins | |
| SG11201808270PA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201810628XA (en) | Nasal pharmaceutical compositions with a porous excipient | |
| SG11201500005SA (en) | Pyrimidine pyrazolyl derivatives | |
| SG11201808138YA (en) | Substituted indole derivatives as dengue viral replication inhibitors | |
| SG11201808106YA (en) | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation | |
| SG11201908465QA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201908512YA (en) | Somatostatin modulators and uses thereof | |
| SG11201810371XA (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
| SG11201807827VA (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
| SG11201408240TA (en) | Treatment of motor and movement disorder side effects associated with parkinson's disease treatments | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201406973PA (en) | Complement pathway modulators and uses thereof |